This could be huge for Sorrento (2nd or 3rd is fine)...might get idea from Lilly's CEO on antibody and FDA etc- he will be on Crazy Cramer tonight
So far, Lilly's lead antibody candidate has shown mixed promise in human tests, with data from a phase 2 trial release this week showing two of three tested doses didn't top placebo in reducing patients' viral load at the 11-day mark.
Only the 2,800-milligram dose met the primary endpoint. The other two doses—700 milligrams and 7,000 milligrams—did no better than placebo. Typically, the highest dose of a drug has the biggest effect.
Market Data 
Markets 
AI
